Vmbook Online ordering

Theratechnologies Inc

I'm glad to help you with that! THERF is the ticker symbol for Theravance Biopharma, a public biotechnology company that is listed on the NASDAQ stock exchange. The company focuses on the discovery, development, and commercialization of medicines for various therapeutic areas, including respiratory diseases, bacterial infections, and central nervous system disorders.

Here are some key points about Theravance Biopharma's financials, earnings, and growth:

* As of December 31, 2021, Theravance Biopharma had cash, cash equivalents, and short-term investments of approximately $756.5 million.

* For the full year 2021, the company reported revenue of $228.4 million, up from $156.6 million in 2020. The increase was primarily due to the recognition of deferred revenue related to the collaboration and license agreement with Janssen Biotech.

* In 2021, Theravance Biopharma recorded a net loss of $49.5 million, compared to a net loss of $79.4 million in 2020.

* The company's research and development expenses for 2021 were $232.6 million, up from $210.1 million in 2020. This increase was primarily due to higher clinical development costs related to the company's late-stage therapeutic candidates.

* Theravance Biopharma's lead product candidate is called "YUPELRI" (revefenacin), which is a once-daily, nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). In 2021, YUPELRI generated net sales of $137.4 million, up from $72.5 million in 2020.

* The company has several other therapeutic candidates in various stages of clinical development, including TD-8236, a lung-selective pan-Janus kinase (JAK) inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis, and TD-1607, an orally administered glycoprotein IIb/IIIa receptor antagonist for the prevention of major adverse cardiovascular events in patients with acute coronary syndrome.

Theravance Biopharma's financials and growth prospects are subject to various risks and uncertainties, including the development and commercialization of its therapeutic candidates, regulatory approvals, competition, and market conditions. Investors should carefully consider these and other factors when evaluating the company's financials and prospects.